In Colorado, DMC Biotechnologies has completed downstream processing for its first product, the amino acid L-alanine. The downstream processing was done at EW Biotech in Leuna, Germany following the successful demonstration of commercial scale fermentation at the same site in March.
The purification of L-alanine from the fermentation broth was successfully completed for more than 6,000 kg of product. Product release testing has demonstrated that rigorous customer specifications for L-alanine were met.
Demonstration of the purification process and achievement of product specifications is the final proof point for DMC’s approach to producing L-alanine. As announced on 21 April 2021, L-alanine is now available at commercial scale following execution of a manufacturing agreement with Conagen.
Matt Lipscomb, Ph.D., CEO & Co-Founder of DMC said, “We recently announced the successful full commercial-scale demonstration of our fermentation process. Historically, fermentation scale-up has been a major stumbling block for early-stage companies. Delivering products to customers also requires successful purification and demonstration that the product meets the required specifications. We now have product with demonstrated quality metrics enabling customer adoption.”
